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Abstract It is well established that several inXamma-
tory-type conditions, such as arthritis, diabetes, cardio-
vascular disease, and irritable bowel disease exist
comorbidly and at an increased incidence in patients
with psoriasis. Psoriasis and other associated diseases
are thought to share common inXammatory pathways.
Conditions such as these, with similar pathogenic
mechanisms involving cytokine dysregulation, are
referred to as immune-mediated inXammatory diseases
(IMIDs). Considerable evidence for the genetic basis
of cormobidities in psoriasis exists. The WHO has
reported that the occurrence of chronic diseases,
including IMIDs, are a rising global burden. In addi-
tion, conditions linked with psoriasis have been associ-
ated with increasing rates of considerable morbidity
and mortality. The presence of comorbid conditions in
psoriasis patients has important implications for clini-
cal management. QoL, direct health care expenditures
and pharmacokinetics of concomitant therapies are
impacted by the presence of comorbid conditions. For
example, methotrexate is contraindicated in hepatic
impairment, while patients on ciclosporin should be
monitored for kidney function. In addition, some
agents, such as beta blockers, lithium, synthetic anti-
malarial drugs, NSAIDs and tetracycline antibiotics,
have been implicated in the initiation or exacerbation
of psoriasis. Consequently, collaboration between phy-
sicians in diVerent specialties is essential to ensuring
that psoriasis treatment beneWts the patient without
exacerbating associated conditions.
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Psoriasis: from gene to clinic
A satellite symposium held at the Royal College of
Physicians, London, United Kingdom, in December
2005 investigated the associations between psoriasis,
comorbid diseases and concomitant therapy and their
signiWcance for long-term patient treatment. The pro-
gramme generated substantial debate and raised some
clinically signiWcant issues, which are further outlined
here.
Introduction
Psoriasis is a common, chronic, immune-mediated
inXammatory disease with a recognised genetic pre-
disposition. It has been observed that, while the fre-
quency of skin conditions such as acne, urticaria and
atopic dermatitis are reduced in patients with psoriasis
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population, the frequency of some noncutaneous,
although related, conditions is signiWcantly increased
[26, 53]. Perhaps the best known noncutaneous condi-
tion associated with psoriasis is joint disease, mostly
expressed as psoriatic arthritis (PsA). In hospitalised
psoriasis patients, a diagnosis of PsA [according to the
European Spondyloarthropathy Study Group (ESSG)
criteria] was present in 7.7% (71/936) of patients; how-
ever, many more patients also reported paresthesias
(12.3%), arthralgia (7%), stiVness (4.2%), swelling
(3.7%) and ankylosis (1.2%) without meeting all of the
ESSG criteria for PsA [19]. Further estimates place the
occurrence of PsA in patients with psoriasis at upwards
of 30% [31]. An additional study by Zachariae et al.
[83] established even higher rates for psoriasis with
joint involvement in 5,795 members of psoriasis associ-
ations from the Nordic countries and 702 patients seen
by Nordic dermatologists. The result showed that
upwards of 30% of all patients who presented with pso-
riasis were also diagnosed with arthritis by their derma-
tologist or a rheumatologist. In a recent study in a
geographically deWned population in Norway Madland
et al. [41] found a prevalence of PsA in 2 per 1,000
inhabitants, which corresponds to about 10% in
patients with psoriasis assuming a prevalence of psoria-
sis of 2%.
These results demonstrate that the prevalence of
arthritis in patients with psoriasis may actually be
higher than the previously accepted rate of 7% [83].
InXammatory bowel disease is also more frequently
observed in patients with psoriasis. An increased rela-
tive risk for Crohn’s disease (CD) of 2.9 was found to
be associated with a prior diagnosis of psoriasis in a
Swedish case-control study [54]. Conversely, patients
with CD are about seven times more likely to develop
psoriasis than controls [5, 37, 82].
Analysis of data from more than 40,000 dermatolog-
ical inpatients with psoriasis compared with control
patients with nonpsoriatic skin diseases (adjusting for
age and gender) revealed high ratios of observed ver-
sus expected frequencies for obesity (2.05, P < 0.05),
hypertension (1.90, P < 0.01), heart failure (1.83, P <
0.001) and diabetes mellitus (1.47, P < 0.05) [26]. An
additional analysis (retrospective chart review, 1997–
2000) of 753 patients from an academic dermatology
practice also conWrms the presence of comorbidities in
patients with psoriasis [53]. In fact, a comorbid diagno-
sis was conWrmed in 551 patients (73%), with hyperten-
sion, dyslipidemia, diabetes and heart disease being the
most common comorbidities identiWed [53]. Further-
more, patients with psoriasis appear to be at increased
risk of atherosclerosis, which may at least in part be
explained by an abnormal plasma lipid metabolism;
serum lipoprotein (a) and triglycerides are signiWcantly
increased in patients with psoriasis compared with
healthy control subjects [73], while high-density lipo-
protein (HDL) cholesterol is signiWcantly decreased
[60]. Indeed, in patients with PsA, alterations of the
lipid proWle suggest similarities to the diabetic lipid
proWle, which is known to substantially increase cardio-
vascular risk [30].
Nearly 30 years ago it was reported that the rates of
occlusive vascular disease were signiWcantly higher in
dermatological patients with psoriasis than those with-
out and that the risk was greater in patients with pre-
disposing factors [44]. Metabolic syndrome has since
been identiWed as a clustering of metabolic abnormali-
ties in individuals and is associated with a threefold
increase in type 2 diabetes and a twofold increase in
cardiovascular disease [86]. The most recent deWnition
of metabolic syndrome requires central obesity (deW-
ned as body mass index >30 kg/m2) plus any two of the
following: elevated plasma triglycerides, reduced HDL
cholesterol, elevated blood pressure and raised fasting
plasma glucose (Table 1). Such clustering of risk fac-
tors has been observed in patients with psoriasis [26].
Psoriasis, especially in patients with more severe dis-
ease, has also been associated with other factors that
can increase cardiovascular risk, thereby increasing
morbidity and mortality. Alcoholism and liver cirrhosis
are reportedly more common in psoriasis [39] with a
reported prevalence of alcoholism of 18% among pso-
riatic patients compared with 2% in other dermato-
logic controls [22, 46]. Cigarette smoking has also been
associated with psoriasis. A recent case-control study
revealed that the risk of psoriasis was higher in ex-
smokers and current smokers than in those who never
smoked (odds ratios of 1.9 and 1.7, respectively), and
smoking was strongly associated with the occurrence of
pustular lesions (odds ratio = 5.3 for smokers) [48]. In a
cross-sectional study, patients with psoriasis that
enrolled in the prospective Utah Psoriasis Initiative
had a signiWcantly higher prevalence of obesity and
smoking than the general population of Utah
(P < 0.001 for both). The prevalence of obese smokers
was signiWcantly higher (P < 0.001) [27].
A number of psychiatric/psychological comorbidi-
ties have also been observed in patients with psoriasis
[22]. An association between psoriasis and stressful life
events in the year preceding diagnosis has been
reported, suggesting that psychological stress may have
a role in the pathogenesis of psoriasis [48]. Further-
more, psoriasis-related stress can play a role in the
exacerbation of psoriasis, and greater stress reactivity
has been associated with onset of psoriasis at an earlier123
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and diYculties with verbal expression of emotions
(especially anger) have been reported in various cross-
sectional surveys [22]. Severely aVected psoriatic inpa-
tients (>30% body surface area aVected) were likely to
suVer clinical depression and suicidal ideation (7.2%);
however, suicidal ideation was still relatively high
(2.5%) in less severely aVected outpatients (<30% total
body surface area aVected) and comparable to the
reported prevalence among general medical patients
(2.4–3.3%) [21].
These identiWed diseases associated with psoriasis
have led clinicians to look at underlying mechanisms that
might be involved and start considering how managing
comorbid conditions may impact treatment selection and
outcome for the psoriasis patient.
Common inXammatory pathways in psoriasis 
and associated diseases
The immune system has been strongly implicated in
the pathogenesis of psoriasis that resembles a T cell-
mediated, autoimmune, inXammatory disease [7]. T
cells are found in the dermis and epidermis and are
accompanied by increased numbers of dermal den-
dritic cells, macrophages and mast cells [51]. It is
thought that a stimulus (such as trauma or infection)
triggers a plexus of cellular events by inciting a cascade
of cytokines, creating an inXammatory response.
Dendritic cells and T cells become activated with the
formation of an immunological synapse—a multimo-
lecular complex at the T cell-antigen-presenting cell
interface that facilitates immune cell interactions. Once
activated, dendritic antigen-presenting cells and T cells
release cytokines, chemokines and growth factors,
which trigger keratinocyte proliferation, altered diVer-
entiation and an angiogenic tissue response, giving rise
to psoriatic lesions (Fig. 1).
Other inXammatory diseases, such as rheumatoid
arthritis (RA) and CD, are thought to involve similar
pathogenetic mechanisms. Recent research has shown
that inXammation plays a key role in atherosclerosis
[24]. A T-cell inWltrate is always present in atheroscle-
rotic lesions, with activated T cells producing a type 1
helper (Th1) response. Psoriasis is up to seven times
more common in patients with CD than in controls [37,
82] and, as discussed previously, there is often joint
involvement in psoriasis. Such extracutaneous manifes-
tations of the disease substantiate that psoriasis is a sys-
temic disease and not just a skin disease [14].
The term immune-mediated inXammatory disease
(I.M.I.D.) has been developed to describe conditions,
such as psoriasis, CD and RA, with common inXamma-
tory mechanisms described above involving cytokine
dysregulation. This term also encompasses type 1 dia-
betes mellitus, ulcerative colitis, systemic lupus erythe-
matosus, multiple sclerosis, ankylosing spondylitis and
uveitis and may further be expanded to include asthma
and atherosclerosis [79].
Atherosclerosis and rheumatoid arthritis
The prevalence of coronary artery atherosclerosis has
been found to be increased in patients with chronic
inXammatory conditions, such as RA and systemic
lupus erythematosus [3, 10]. Excess mortality due to
coronary heart disease in RA patients was Wrst
observed in 1953 [11]. In a study of 236 RA patients, the
age- and sex-adjusted incidence rate ratio of incident
Table 1 Diseases associated with psoriasis [65]
The prevalence of diseases in plaque-type psoriasis patients (n = 581) was compared with hospital-based controls (n = 1,044) and a pop-
ulation-based survey (RKI sample; n = 4,705). Common odds ratios adjusted for age and sex are presented with their 95% conWdence
intervals (95% CI), f not signiWcant
a Due to low numbers, only adjusted for sex
*P < 0.05; ** P < 0.01; ***P < 0.0001 by Mantel–Haenszel test




RKI sample OR (95% CI)
Diabetes mellitus type I 11 (1.9) 3.99 (1.30–12.2)* 6.34 (2.80–14.3)***
Diabetes mellitus type II 68 (11.7) 2.48 (1.70–3.61)** 2.07 (1.50–2.85)***
Arterial hypertension 127 (21.9) 3.27 (2.41–4.43)*** 1.39 (1.09–1.77)*
Hyperlipoproteinemia 30 (5.2) 2.09 (1.23–3.54)** 0.83 (0.54–1.28)f
Coronary heart disease 32 (5.5) 1.77 (1.07–2.93)* 0.93(0.60–1.43)f
Metabolic syndrome 25 (4.3) 5.92 (2.78–12.8)*** 2.20 (1.41–3.43)**
Alcohol consumption none 
vs. moderate
246 (42.3) 2.78 (2.14–3.62)*** 2.03 (1.62–2.55)***
None vs. regularly 75 (12.9) 3.33 (2.20–5.05)*** 2.00 (1.45–2.77)***
None vs. heavya 24 (4.1) 3.61 (1.85–7.07)*** 8.50 (5.28–16.8)***
Cigarette smoking 264 (45.4) 2.96 (2.27–3.84)*** 2.49 (2.00–3.10)***123
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After adjusting for cardiovascular risk factors such as
age, weight and smoking status, this Wgure decreased
slightly to 3.17, suggesting that there are additional
mechanisms responsible for cardiovascular disease in
RA. The risk of cardiovascular disease increases with
disease severity (eg, number of joints involved) and
disease duration [64, 75]: severe coronary artery calciW-
cation is more likely in patients with established dis-
ease (>10 years) compared with controls after
adjusting for cardiovascular risk factors (odds
ratio = 3.42, P = 0.002) [10]. However, there is some
emerging evidence for increased atherosclerotic dis-
ease in early RA [32].
The lipid proWle in RA patients is directly aVected by
the systemic inXammatory response (active inXammation
lowers HDL cholesterol, which leads to increased cardio-
vascular risk) [75]. Endothelial dysfunction, which under-
lies atherosclerotic plaque development, is associated
with markers of systemic inXammation, such as C-reac-
tive protein (CRP), soluble adhesion molecules (sICAM-
1 and sE-selectin), IL-6 and TNF-alpha (TNF) [24, 38,
78]. Indeed, treatment with the anti-TNF agent inXixi-
mab, which aVects expression of all markers described
above, has been shown to improve endothelial function
in RA patients [28].
Atherosclerosis and psoriasis
An increase in cardiovascular disease has been
observed in psoriasis patients [39, 44] and has been
shown to be related to disease severity and age of
onset [42, 55, 62]. An increased incidence of tradi-
tional cardiovascular risk factors is frequently
reported [26, 42, 56]. In psoriatic patients with a his-
tory of at least one hospital admission due to psoriasis,
there is about a 50% increase in cardiovascular death
as compared with the general population [standar-
dised mortality ratio (SMR) = 1.52]. In those patients
with 3 or more hospital admissions, the SMR
increased to 1.82 and in those patients admitted at
younger ages (20–39 years at Wrst admission), the
SMR increased to 2.62 [42]. However, the SMR was
not increased in those treated as outpatients only,
indicating a relationship to disease severity. In
patients with PsA, an increase in mortality has also
been observed (SMR = 1.65 in males and 1.59 in
females) and the largest single cause of death is myo-
cardial infarction (27.6%) [80]. 
Unfortunately, there is a shortage of published stud-
ies corrected for traditional risk factors and no pub-
lished study has formally assessed systemic vasculature
inXammation in psoriasis.
Fig. 1 InXammatory path-
way in psoriasis [50]. Working 
model for immunopathogene-
sis of psoriasis. Multiple stages 
are proposed for traYcking 
patterns of immunocytes, 
involving signals in which 
symptomless skin is converted 
into a psoriatic plaque. Key 
inXammatory events include 
intraepidermal traYcking by 
CD8+ T cells and neutrophils. 
Reproduced with permission 
from J Clin Invest (2004, 
113:1664–1675). Copyright 
2004, The American Society 
for Clinical Investigation123
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ated inXammatory conditions and a number of similari-
ties exist between their pathogenetic mechanisms.
Numerous factors have been shown to be increased in
the serum of psoriatic patients including apolipopro-
tein E (ApoE), vascular endothelial growth factor
(VEGF), sICAM-1, IL-8, soluble interleukin2 receptor
(sIL-2R) and TNF [9, 12, 14, 15]. sICAM-1 and sIL-
2R are soluble T-cell products [15]. ApoE plays a cen-
tral role in lipoprotein metabolism and has been found
to be signiWcantly raised in patients with psoriasis, indi-
cating that abnormal metabolism of lipoprotein exists
in psoriasis patients [81]. Furthermore, the dyslipidae-
mic proWle exhibited in psoriasis has been shown to
modify dendritic cell functions in skin [1]. The
impaired dendritic cell emigration from the skin paral-
lels impeded migratory clearance of monocyte-derived
dendritic cell-like cells from atherosclerotic plaques.
VEGF mediates endothelial cell mitogenesis and
enhances vascular permeability [4]. In psoriasis, VEGF is
thought to promote localised angiogenesis and in severe
psoriasis may act on renal vasculature to induce hyper-
permeability with consequent proteinuria [12]. A role for
VEGF has been postulated in the atherosclerotic process
as changes in levels of VEGF and its receptors are pres-
ent in atherosclerosis, and angiogenesis may play a role in
plaque development and destabilisation [4].
Genetic basis of comorbidities
There is considerable evidence for a genetic element in
psoriasis. About 30% of individuals with psoriasis have
an aVected Wrst-degree relative [69], and Wrst-degree
relatives are at a Wve to tenfold increased risk for
developing psoriasis themselves [70]. Concordance
rates for psoriasis are three to four times higher in
monozygotic twins than dizygotic twins [6], and twin
and family studies show that 60–90% of the variance in
psoriasis liability is due to genetic factors. Finally, link-
age and association to the major histocompatability
complex (MHC) region has been repeatedly demon-
strated [58]. However, the presence of many diVerent
phenotypes means that not all psoriasis is the same and
polygenic inheritance is likely.
Interestingly, by analysing gene polymorphisms of
the receptor of advanced glycation end products
(RAGE) in patients with plaque-psoriasis seems to be
linked to a genetic risk for cardiovascular disorders in
psoriasis patients [76].
A combination of disease-speciWc and inXammatory
modifying genes interacting with the environment likely
determines the risk of comorbidity. A major susceptibil-
ity gene (Psoriasis Susceptibility 1 or PSORS1) is located
in the MHC class I region and maps to an approximately
300-kb interval containing HLA-C and 10 other genes in
strong linkage disequilibrium with it [25, 47, 77]. Very
recently, through a combination of genomic sequencing
and haplotype analysis, HLA-Cw6 itself has been identi-
Wed as the major disease allele at PSORS1 [47].
The observation that bacterial infections are signiW-
cantly less common in psoriasis patients with an age of
onset ·40 years while immunological skin disorders
(allergic contact dermatitis, urticaria and atopic derma-
titis) are reduced regardless of age of onset suggests a
genetic link between resistance to infection and early-
onset psoriasis [26].
Chronic tonsillitis has been observed over three
times more frequently than would be expected in
patients with psoriasis [26]. Interestingly, psoriasis is
not associated with other forms of streptococcal infec-
tion, suggesting a speciWc role for the tonsils [20].
Recently, identical T-cell receptor rearrangements
have been found in the tonsils and lesional skin of pso-
riatic patients [17]. The prevalence of streptococcal
infection during sore throat was 10 times higher in peo-
ple with psoriasis than in controls and can exacerbate
chronic plaque psoriasis [20]. There was, however, no
diVerence in asymptomatic carriage between psoriasis
patients and controls [20]. These results suggest either
that psoriatic patients are more susceptible to strepto-
coccal infection or that they respond more vigorously
to it and are more likely to develop symptoms.
This apparently defective response to streptococci
combined with resistance to a variety of skin infections
in psoriasis patients provides an interesting paradox. It
is known that streptococcal (and other) infections may
initiate psoriasis in genetically predisposed individuals,
and psoriasis is characterised by strong Th1 immune
deviation. Once the psoriatic cascade has been initi-
ated, increased skin and/or systemic inXammation
directed by Th1 cells may be responsible for a lower
risk of other infections. Interestingly, bacterial infec-
tion (principally with Chlamydia pneumoniae) has also
The increased cardiovascular risk in psoriasis may result from
• The increased prevalence of associated risk factors, such as 
smoking, obesity, hypertension and alcohol misuse.
• The use of dyslipidaemic therapies, such as corticosteroids, aci-
tretin and ciclosporin.
• An associated unfavourable lipid proWle (high triglycerides, low 
HDL).
• Endothelial dysfunction.
• Uncontrolled inXammation. 
• Combination of some or all of the above.123
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[36, 63]. A phenomenon similar to that seen in psoriasis
could contribute to increased risk of cardiovascular dis-
ease.
Clinical importance of comorbidities in psoriasis
According to the World Health Organization (WHO),
the occurrence of chronic disease is a rising global bur-
den. In 2005, all chronic diseases accounted for 72% of
the total global burden of disease in the population
aged 30 years and older (Fig. 2) [68]. More than 80% of
the burden of chronic diseases occurs in people under
age 70 years. While psoriasis causes signiWcant morbid-
ity, it is not generally associated with mortality; how-
ever, conditions linked with psoriasis are associated
with excess mortality [56]. For example, the higher
prevalence of smoking in the psoriatic population may
explain why psoriasis has been associated with lung
cancer in middle-aged women [39]. A registry of 5,687
patients admitted to the hospital for psoriasis between
1973 and 1984 who were followed for up to 22 years
until 1995 found a signiWcantly increased mortality for
both alcohol- and smoking-related causes [56].
An increased rate of cardiovascular events has been
observed in patients with psoriasis [39, 44], and it
appears to be related to the severity of disease and age
of onset [42, 55, 62]. Worldwide, cardiovascular disease
is estimated to be the cause of 30% of all deaths in 2005
making it the leading single cause of death worldwide
[68]. IdentiWcation and treatment of modiWable risk
factors in patients with psoriasis could result in a lower
associated cardiovascular morbidity and mortality [55].
Conceptually, the eVective systemic control of inXam-
mation in psoriasis could also lead to improvements in
comorbid conditions driven by inXammation.
Implications of comorbidities
The presence of comorbid conditions in psoriasis
patients can have some important implications for clin-
ical management. The general health status of the
patient will be aVected by all of these associated dis-
eases, with substantial impact on quality of life (QoL)
[33, 74]. The precise impact of comorbid conditions on
QoL in psoriasis patients has not been quantiWed; how-
ever, it is known that the presence of joint involvement
can signiWcantly reduce health-related QoL [40] and
that arthritis and arthralgia are important related fac-
tors aVecting QoL in patients with psoriasis [83]. In
fact, the eVects of psoriasis on QoL are comparable to
the eVects observed from other major chronic diseases
[59]. The authors performed an analysis of 317 patients
with psoriasis and found that these patients reported a
reduction in physical and mental functioning compara-
ble to that observed in patients with cancer, arthritis,
hypertension, heart disease and depression [59].
A US study looking at the direct health care expen-
ditures associated with psoriasis found that psoriasis
patients treated with systemic therapy or phototherapy
have signiWcantly more comorbidities and higher mean
total health care expenditures compared with non-pso-
riasis patients. Furthermore, selected comorbidities
lead to signiWcantly higher mean total health care
expenditures in those patients with psoriasis than in
those with the same condition without psoriasis [13].
Many of the conditions associated with psoriasis
could aVect the way drugs are absorbed and eliminated
from the body. For example, alcoholism impairs liver
function, obesity aVects drug distribution in the body,
diabetes can impair kidney function, inXammatory
bowel disease can reduce absorption from the gastroin-
testinal tract and smoking can impact the eYcacy of
some drugs [85]. Of course, the presence of these con-
ditions will also lead to increased polypharmacy,
increasing the likelihood of drug interactions and mak-
ing it harder to implement an ‘ideal’ psoriasis treat-
ment in individuals [34].
Fig. 2 WHO projected major causes of death 2005 [67]. The
occurrence of chronic disease is a rising global burden and ac-
counted for 72% of the total global burden of disease in the pop-
ulation aged 30 years and older in 2005. Reproduced with
permission from Lancet (2005, 366:1578–1582). Copyright 2005,
Elsevier Ltd123
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bid conditions are
• Focus on inXammation control.
• Consider impact on patient as a whole.
• Monitor all associated diseases.
Drug interactions in psoriasis
It has been suggested that some drugs may trigger or
exacerbate psoriasis. The most commonly proposed
causative agents are beta blockers, lithium, synthetic
antimalarial drugs, nonsteroidal anti-inXammatory
drugs (NSAIDs) and tetracycline antibiotics [72].
Analysis of co-medication according to patients’ Wles
in 1203 consecutive inpatients hospitalised for treat-
ment of severe psoriasis was conducted between 2003
and 2005 in 9 dermatology departments in Germany
[84]. The mean age of patients was 50 years (55.9%
female, 44.1% male). The mean Psoriasis Area and
Severity Index was 26.0, average body mass index was
27.5 and mean age of Wrst manifestation was
33.5 years. About one third of patients were found to
be taking no systemic medication (34.4%), and 42.4%
were taking three or fewer systemic agents. However,
nearly a quarter (23.2%) were taking more than three
systemic medications and of these, 11.1% were taking
more than ten medications (Table 2). Therefore, phy-
sicians caring for patients with psoriasis may consider
withdrawal of agents that potentially exacerbate this
condition. Further analysis suggests that comorbid
cardiac and metabolic disorders are common in these
patients: hypertension, 28.8%; type 2 diabetes, 10.5%;
dyslipidaemia, 12.5%; hyperuricaemia, 5.3%; arrhyth-
mias, 5.1%; coronary artery disease, 3.2%; and car-
diac insuYciency, 2.1%. The presence of renal
insuYciency (2.7%) and liver cirrhosis (2.4%) were
also noteworthy.
Risk of interactions with psoriasis therapies
There is a high risk of drug interactions with both ciclo-
sporin and methotrexate, while retinoids and leXuno-
mide exhibit a lower risk of drug–drug interactions.
Conversely, treatments with biologics, such as TNF
inhibitors, and fumaric acid esters have no known risk
of interactions. A number of medications can cause
photosensitivity, which is an issue for any UV treat-
ment of psoriasis (e.g., tetracyclines [doxycyclin] and
thiazide diuretics) [67].
EVect of psoriasis treatment on comorbidities
The importance of considering the impact of treatment
of diseases associated with psoriasis cannot be stressed
enough. Working with physicians in diVerent special-
ties (e.g., rheumatology, gastroenterology and cardiol-
ogy) would allow physicians an opportunity to ensure
that the psoriatic treatments do not worsen the associ-
ated condition and where possible provide additional
beneWts.
BeneWts of psoriasis therapy on comorbid conditions
Since many comorbid conditions have inXammatory
mechanisms in common with psoriasis, drugs targeting
inXammation and/or suppressing the immune response
are often eVective in treating both psoriasis and related
comorbidities. A number of treatments have shown
some eYcacy in treating both psoriasis and PsA includ-
ing methotrexate, ciclosporin, leXunomide, etanercept
and inXiximab [2, 18, 31, 45]. The TNF inhibitors eta-
nercept and inXiximab have demonstrated halting of
joint degradation [45].
Crohn’s disease
There are few treatments that are eVective in both pso-
riasis and CD. Azathioprine and 6-mercaptopurine are
often used in CD, and they have also shown some
eYcacy in PsA in small, uncontrolled trials; however,
toxicity is likely to restrict their use [50]. Low-dose
methotrexate has shown some eYcacy in CD patients
resistant to other therapies; however, its usefulness in
the long term has yet to be established [66]. InXiximab
has been shown to be eVective in both attaining and
maintaining remission in CD patients [23] as well as in
the treatment of extra-intestinal cutaneous manifesta-
tions [61]. Conversely, etanercept has not been shown
to be eVective in the treatment of CD and may even
worsen the condition [52]. The diVerence between the
Table 2 Percentage of psoriasis patients receiving medications
for comorbid disease [84]
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thought to be due in part to their diVerent mechanisms
of binding TNF. InXiximab has higher aYnity than
etanercept, binding more forms of TNF, and may
induce cell apoptosis [35].
Cardiovascular disease
Evidence for the improvement of psoriasis-associated
cardiovascular risk following psoriasis treatment is lim-
ited to a trial of methotrexate in patients with psoriasis
or RA [57]. Patients prescribed methotrexate had a sig-
niWcantly reduced risk of vascular disease compared
with those who did not receive methotrexate (psoriasis,
relative risk [RR] = 0.73; RA, RR = 0.83). Further-
more, risk reduction was greater in those who received
a low cumulative dose of methotrexate (psoriasis,
RR = 0.50; RA, RR = 0.65) and in those patients also
receiving concomitant folic acid (psoriasis, RR = 0.56;
RA, RR = 0.77). Further work in RA has suggested
that anti-TNF therapy may provide some cardiovas-
cular protection [29]. A comparison of two cohorts,
one receiving TNF inhibitors and one receiving stan-
dard therapy (derived from patient registries),
revealed a reduced age–sex adjusted incidence rate of
Wrst cardiovascular event in those receiving TNF
inhibitors compared with controls (14.0/1,000 person–
years at risk vs. 35.4/1,000 person–years). After con-
trolling for disability, the age–sex adjusted rate ratio
was 0.46 (P = 0.013) in the anti-TNF-treated cohort
versus the not-treated cohort.
Statins are used to lower lipids in people at risk for
cardiovascular events and have been shown to reduce
cardiovascular morbidity and mortality; however, sta-
tins have also been shown to have anti-inXammatory
properties [24, 43]. Statins down-regulate the expres-
sion of adhesion molecules and the expression of Th1
chemokine receptors on T cells, as well as block the
expression of TNF and interferon-gamma in macro-
phages among other immunomodulatory actions [49].
A double-blind, placebo-controlled trial in 116 patients
with RA demonstrated that 40 mg atorvastatin daily, in
addition to existing RA therapy, produced a signiWcant
reduction in disease activity (P = 0.004), a signiWcant
reduction in inXammatory markers (CRP 50%,
P < 0.0001; ESR 28%, P = 0.005) and a signiWcant
reduction in swollen joint count (¡2.69 vs ¡0.53;
P = 0.0058) compared with placebo [43]. In addition,
simvastatin treatment has been shown to signiWcantly
reduce serum CRP and TNF in patients with RA and
improve endothelial function [71]. Therefore, it has
been suggested that statins may have beneWcial eVects
in inXammatory dermatological conditions including
psoriasis, and the results of controlled trials are
awaited [49].
Potential drawbacks of psoriasis therapy on comorbid 
conditions
Other common comorbidities could inXuence the
choice of psoriasis therapies available to the dermatol-
ogist. Ciclosporin can induce hyperglycaemia and aci-
tretin can alter glucose tolerance; therefore, they are
best avoided in diabetic patients. Methotrexate has
been reported to precipitate diabetes and increase
insulin requirements due to increased disease progres-
sion [8]. Ciclosporin is contraindicated in patients with
uncontrolled hypertension and acitretin is contraindi-
cated in hyperlipidaemia. Methotrexate and acitretin
are contraindicated in the presence of hepatic impair-
ment, which may result from psoriasis-associated alco-
hol misuse, while ciclosporin may need dosage
adjustment and regular monitoring of kidney function
since renal dysfunction is a known side eVect [8].
Drug interactions and precipitating disease in psoriasis
A diagnosis of psoriasis also has implications regarding
treatment for physicians from specialities other than
dermatology. The potential of some drugs (eg, angio-
tensin-converting enzyme inhibitors, beta blockers,
NSAIDs) to ‘trigger’ psoriasis means that these drugs
should be avoided where possible and awareness of
this potential should be raised. The potential for drug
interactions with some psoriasis drugs is high and this
should also be considered when designing therapeutic
regimens. Furthermore, the increased risk of cardio-
vascular events associated with psoriasis should be con-
sidered when conducting global cardiovascular risk
assessments. If possible, lower cut-oV points for treat-
ment should be used in psoriasis patients in an eVort to
take into consideration their overall cardiovascular
risk.
Discussion and conclusions
Psoriasis is a multifaceted systemic condition that is not
restricted to cutaneous symptoms. There is a need for
further research to fully understand the reasons for
comorbidities and their implications on treatment and
management of psoriasis patients. Data are required to
fully characterise risk of cardiovascular disease in pso-
riasis patients and whether treatment can impact this
level of risk. Could eVective (systemic) treatment of pso-
riasis reduce the risk of comorbidities or, conversely,123
Arch Dermatol Res (2006) 298:309–319 317could eVective treatment of comorbidities improve
psoriasis? Investigation of the genetics of psoriasis and
related inXammatory conditions may provide insight
into their pathogenesis and points of commonality,
which could reveal novel drug targets
However, while research is conducted, there is a
pressing need for education about comorbidities in
psoriasis. Dermatologists need to be aware of the like-
lihood of comorbid conditions to ensure their detection
and that psoriasis is managed with consideration of the
possible impact on associated comorbid inXammatory
conditions. Similarly, physicians from other specialities
should be aware of the potential impact of their man-
agement strategies on psoriasis and take care not to
exacerbate psoriasis when treating associated condi-
tions. A focus on rapid and profound systemic control
of inXammation in psoriasis may have added beneWts
by controlling inXammation associated with comorbid
conditions. It is clear that TNF is a central mediator in
psoriasis and many of the recognised associated dis-
eases. Knowledge and awareness of the common
inXammatory processes involved should provide the
opportunity to more eVectively treat the common
causes of inXammatory conditions beneWtting both
physicians and patients. Managing the psoriasis patient
as a whole with integrated therapy is likely to maximise
outcomes.
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